Drug Trial Radar · NCT07109414
Trial of NP-G2-044 (Prilukae) Combined With PLD for Treatment of Platinum-Resistant Ovarian Cancer (ULTIMUS-1)
Last checked: Nov 19, 2026Latest source record: Mar 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
380
Planned (sponsor's estimate)
Start
Dec 29, 2025
Primary completion
Oct 25, 2028
Study completion Oct 24, 2029
Sponsor
- Lead sponsor
- Novita Pharmaceuticals, Inc.Industry
- Sponsor type
- Industry
- Collaborators
- Gynecologic Oncology Group
- First posted
- Aug 7, 2025
Design
- Study type
- Interventional
- Phase
- Phase 2 / Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- Female only, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of the study is to identify the optimal dose level of NP-G2-044 in combination with standard of care (SOC) pegylated liposomal doxorubicin (PLD), and to compare the efficacy and safety of NP-G2-044+PLD vs. PLD alone in participants with platinum-resistant ovarian cancer (PROC).
Conditions
- Platinum-resistant Ovarian Cancer
Interventions
NP-G2-044Drug
NP-G2-044 will be provided as a tablet via oral route of administration in the study.
PLDDrug
PLD will be provided as an infusion via intravenous route of administration in the study.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Part A (Dose escalation): Number of participants with adverse events (AEs)Time frame: From first dose until Safety Follow-up (30 days ±7 days after last dose of NP-G2-044) Approximately 2 years
- Part A (Dose escalation): Number of participants with Dose Limiting Toxicities (DLTs)Time frame: Up to 28 days
- Part B (Dose Optimization): Number of participants with AEsTime frame: From Day 1 until Safety Follow-up (30 days ±7 days after last dose of NP-G2-044) Approximately 2 years
- Part B (Dose Optimization): Overall response rate (ORR)Time frame: From randomization until disease progression, death, or withdrawal of consent, whichever occurs first (Approximately 2 years)
- Part B (Dose Optimization): Progression free survival (PFS)Time frame: From randomization until disease progression, death, or withdrawal of consent, whichever occurs first (Approximately 2 years)
- Part C (Phase 3): Progression free survival (PFS)Time frame: From randomization until disease progression, death, or withdrawal of consent, whichever occurs first (Approximately 3 years
Locations
6 sites in 1 country. Site status is shown where the registry gives one.
HonorHealth Cancer Care
Phoenix, Arizona
Trials365
Shreveport, Louisiana
Optimum Clinical Research Group, LLC
Albuquerque, New Mexico
University of Pennsylvania Health System, Perelman Center for Advanced Medicine
Philadelphia, Pennsylvania
Utah Cancer Specialists
Salt Lake City, Utah
University Of Wisconsin Carbone Cancer Center
Madison, Wisconsin
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.